scholarly journals O-34: The UK inflammatory bowel disease (IBD) audit: 3 audits, 700 paediatric ulcerative colitis (UC) inpatients, many clinical messages

2014 ◽  
Vol 8 ◽  
pp. S437
Author(s):  
R.K. Russell ◽  
L. Protheroe ◽  
All IBD Audit Leads
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Inflammatory Bowel ◽  
The Uk

scholarly journals Inflammatory bowel disease: a beast of burden

2011 ◽  
pp. 57-61
Author(s):  
Dawn Farrell
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Social Life ◽  
Symptom Burden ◽  
Complex Disorders ◽  
Inflammatory Bowel ◽  
The Uk

Imagine having to empty your bowel eight or ten times a day and experiencing constant panic and fear about the location of toilet facilities. Imagine experiencing constant tiredness that impacts on all aspects of your life including work, family and social life. These are just two examples of experiences commonly suffered by individuals with a condition called inflammatory bowel disease. These people are burdened with symptoms which impact on their daily lives. This research aims to provide healthcare professionals with an understanding of the extent to which individuals with inflammatory bowel disease experience symptom burden and to identify what symptoms are most problematic. Crohn’s disease and ulcerative colitis collectively termed as inflammatory bowel disease are complex disorders. In the United Kingdom, collectively Crohn’s disease and ulcerative colitis affects approximately one person in every 250 of the population. Ulcerative colitis affects up to 120,000 people in the UK, or every 1 ...

Inflammatory bowel disease: introduction

2011 ◽  
Author(s):  
R. Mark Beattie ◽  
Anil Dhawan ◽  
John W.L. Puntis
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Family History ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
History Of ◽  
Inflammatory Bowel ◽  
The Uk

Inflammatory bowel disease 288• 25 % of inflammatory bowel disease (IBD) presents in childhood, usually as Crohn's disease or ulcerative colitis. The UK incidence is 5.2/100 000 children <16 years of age. Crohn's disease is the more common. Family history of Crohn's disease or ulcerative colitis is common. Both diseases can occur in the same family....

Inflammatory bowel disease: introduction

2018 ◽  
Author(s):  
Akshay Batra ◽  
Mark Beattie
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Genetic Predisposition ◽  
Bowel Disease ◽  
Immune Dysfunction ◽  
Complex Interaction ◽  
Indeterminate Colitis ◽  
Inflammatory Bowel ◽  
The Uk

The incidence of inflammatory bowel disease is 5.2/100,000 children less than 16 years in the UK. Crohn’s disease is the commonest form of inflammatory bowel disease followed by ulcerative colitis and indeterminate colitis. The precise aetiology of inflammatory bowel disease is unknown and reflects a complex interaction between genetic predisposition, immune dysfunction, and environmental triggers.

scholarly journals Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource

Gut ◽  
2020 ◽  
pp. gutjnl-2019-320185 ◽  
Author(s):  
Evangelos Stournaras ◽  
Wendi Qian ◽  
Apostolos Pappas ◽  
You Yi Hong ◽  
Rasha Shawky ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Increased Risk ◽  
Long Term Treatment ◽  
Inflammatory Bowel ◽  
The Uk

ObjectiveThiopurines are widely used as maintenance therapy in inflammatory bowel disease (IBD) but the evidence base for their use is sparse and their role increasingly questioned. Using the largest series reported to date, we assessed the long-term effectiveness of thiopurines in ulcerative colitis (UC) and Crohn’s disease (CD), including their impact on need for surgery.DesignOutcomes were assessed in 11 928 patients (4968 UC, 6960 CD) in the UK IBD BioResource initiated on thiopurine monotherapy with the intention of maintaining medically induced remission. Effectiveness was assessed retrospectively using patient-level data and a definition that required avoidance of escalation to biological therapy or surgery while on thiopurines. Analyses included overall effectiveness, time-to-event analysis for treatment escalation and comparison of surgery rates in patients tolerant or intolerant of thiopurines.ResultsUsing 68 132 patient-years of exposure, thiopurine monotherapy appeared effective for the duration of treatment in 2617/4968 (52.7%) patients with UC compared with 2378/6960 (34.2%) patients with CD (p<0.0001). This difference was corroborated in a multivariable analysis: after adjusting for variables including treatment era, thiopurine monotherapy was less effective in CD than UC (OR 0.47, 95% CI 0.43 to 0.51, p<0.0001). Thiopurine intolerance was associated with increased risk of surgery in UC (HR 2.44, p<0.0001); with a more modest impact on need for surgery in CD (HR=1.23, p=0.0015).ConclusionThiopurine monotherapy is an effective long-term treatment for UC but significantly less effective in CD.

▾ Asacol: mesalazine for ulcerative colitis

1986 ◽  
Vol 24 (10) ◽  
pp. 38-40
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Salicylic Acid ◽  
Small Bowel ◽  
Bowel Disease ◽  
Active Component ◽  
Carrier Molecule ◽  
Amino Salicylic Acid ◽  
Inflammatory Bowel ◽  
The Uk

Sulphasalazine (Salazopyrin) has been used in the treatment of inflammatory bowel disease for more than 40 years. The drug consists of two compounds - sulphapyridine and 5-amino salicylic acid (5-ASA, approved name mesalazine) - joined by a diazo bond. Sulphasalazine is poorly absorbed in the small bowel and so reaches the large bowel where bacteria split the diazo bond, releasing sulphapyridine and mesalazine. The mesalazine moiety is the active component of the drug,1 and probably acts topically in the colon. Mesalazine is absorbed in the ileum, and so is unlikely to be effective in the treatment of ulcerative colitis when given by mouth.2 The sulphapyridine acts as a carrier molecule which prevents absorption in the small bowel; it causes most of the unwanted effects of sulphasalazine. Several different oral preparations have been developed in an attempt to deliver mesalazine to the colon without the need for a toxic carrier. Asacol (Tillots) is the first to be marketed in the UK, and is licensed for use only in patients intolerant of sulphasalazine.

Inflammatory bowel disease

2021 ◽  
pp. 367-394
Author(s):  
Jennie Burch ◽  
Brigitte Collins
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Microscopic Colitis ◽  
Indeterminate Colitis ◽  
Clinical Environment ◽  
Inflammatory Bowel ◽  
The Uk

The inflammatory bowel disease (IBD) chapter explores the umbrella term that encompasses Crohn’s disease, ulcerative colitis, indeterminate colitis and microscopic colitis. These diseases are increasing in incidence in the UK and worldwide. Symptoms can be debilitating and may not be curable. Treatment can include medication, diet and surgery but there can be extra-intestinal of IBD. There will be an in-depth focus on Crohn’s disease and ulcerative colitis to explore the definitions, symptoms, causes and incidence of each disease. Investigations for both diseases are then explained. Concise explorations on the issues related to inflammatory bowel disease, particularly ulcerative colitis and Crohn’s disease can be used within clinical environment by the nurse.

Inflammatory bowel disease in adults

2021 ◽  
pp. 175573802110587
Author(s):  
Umang Qazi
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Gastrointestinal Tract ◽  
Early Diagnosis ◽  
Chronic Inflammation ◽  
Bowel Disease ◽  
Aggressive Treatment ◽  
Inflammatory Bowel ◽  
The Uk ◽  
Two Peaks

Inflammatory bowel disease (IBD) is an umbrella term used to describe a group of disorders characterised by chronic inflammation of the gastrointestinal tract, of which ulcerative colitis and Crohn’s disease are the most common. It is estimated that 500 000 people in the UK currently live with IBD. There are two peaks of incidence, the first of which is between 15 and 30 years of age, with a second smaller peak between 60 and 80 years of age. Its prevalence is ever increasing, and GPs play an important role in early diagnosis, which is the key in reducing the need for aggressive treatment.

Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?

2020 ◽  
Vol 15 (3) ◽  
pp. 216-233 ◽  
Author(s):  
Maliha Naseer ◽  
Shiva Poola ◽  
Syed Ali ◽  
Sami Samiullah ◽  
Veysel Tahan
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Adverse Effects ◽  
Bowel Disease ◽  
Relapse Prevention ◽  
Remission Induction ◽  
Inflammatory Bowel

The incidence, prevalence, and cost of care associated with diagnosis and management of inflammatory bowel disease are on the rise. The role of gut microbiota in the causation of Crohn's disease and ulcerative colitis has not been established yet. Nevertheless, several animal models and human studies point towards the association. Targeting intestinal dysbiosis for remission induction, maintenance, and relapse prevention is an attractive treatment approach with minimal adverse effects. However, the data is still conflicting. The purpose of this article is to provide the most comprehensive and updated review on the utility of prebiotics and probiotics in the management of active Crohn’s disease and ulcerative colitis/pouchitis and their role in the remission induction, maintenance, and relapse prevention. A thorough literature review was performed on PubMed, Ovid Medline, and EMBASE using the terms “prebiotics AND ulcerative colitis”, “probiotics AND ulcerative colitis”, “prebiotics AND Crohn's disease”, “probiotics AND Crohn's disease”, “probiotics AND acute pouchitis”, “probiotics AND chronic pouchitis” and “prebiotics AND pouchitis”. Observational studies and clinical trials conducted on humans and published in the English language were included. A total of 71 clinical trials evaluating the utility of prebiotics and probiotics in the management of inflammatory bowel disease were reviewed and the findings were summarized. Most of these studies on probiotics evaluated lactobacillus, De Simone Formulation or Escherichia coli Nissle 1917 and there is some evidence supporting these agents for induction and maintenance of remission in ulcerative colitis and prevention of pouchitis relapse with minimal adverse effects. The efficacy of prebiotics such as fructooligosaccharides and Plantago ovata seeds in ulcerative colitis are inconclusive and the data regarding the utility of prebiotics in pouchitis is limited. The results of the clinical trials for remission induction and maintenance in active Crohn's disease or post-operative relapse with probiotics and prebiotics are inadequate and not very convincing. Prebiotics and probiotics are safe, effective and have great therapeutic potential. However, better designed clinical trials in the multicenter setting with a large sample and long duration of intervention are needed to identify the specific strain or combination of probiotics and prebiotics which will be more beneficial and effective in patients with inflammatory bowel disease.

scholarly journals The Changing Prognosis of Ulcerative Colitis and Crohn’s Disease by Decades

2021 ◽  
Author(s):  
Burton I Korelitz ◽  
Judy Schneider
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Medical Therapy ◽  
Bowel Disease ◽  
Surgical Intervention ◽  
Inflammatory Bowel

Abstract We present a bird’s eye view of the prognosis for both ulcerative colitis and Crohn’s disease as contained in the database of an Inflammatory Bowel Disease gastroenterologist covering the period from 1950 until the present utilizing the variables of medical therapy, surgical intervention, complications and deaths by decades.

Sign in / Sign up

Export Citation Format

Share Document